Breaking News Instant updates and real-time market news.

BLUE

Bluebird Bio

$84.00 /

-2.97 (-3.41%)

20:08
12/12/19
12/12
20:08
12/12/19
20:08

Bluebird Bio upgraded to Outperform from Perform at Oppenheimer

Oppenheimer analyst Mark Breidenbach upgraded Bluebird Bio to Outperform from Perform with a $135 price target.

BLUE Bluebird Bio
$84.00 /

-2.97 (-3.41%)

12/10/19 Piper Sandler
Bluebird Bio ASH updates 'not enough' to alter Piper's Neutral stance
12/09/19 Stifel
Bluebird Bio share rebound potential dampened by JNJ-4528 news, says Stifel
12/09/19 Wells Fargo
Bluebird Bio price target lowered to $160 from $242 at Wells Fargo
12/09/19 Canaccord
Bluebird Bio price target lowered to $118 from $171 at Canaccord

TODAY'S FREE FLY STORIES

General news
Asian Market Update: » 01:45
02/26/20
02/26
01:45
02/26/20
01:45

Asian Market Update:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

General news
Fed's Kaplan: Virus impact on rates unclear. » 01:35
02/26/20
02/26
01:35
02/26/20
01:35

Fed's Kaplan: Virus…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

General news
Treasury Market Summary » 22:15
02/25/20
02/25
22:15
02/25/20
22:15

Treasury Market Summary:…

Treasury Market Summary: It was another crushing session for Wall Street with the Dow and S&P 500 plunging over 3% late in the day reflecting ongoing fears of the unknown. The spreading COVID-19 virus remained the focal point with some 80k confirmed cases globally and over 2.7k deaths. Though still mostly confined to China, the spread to Italy and Iran continue to frighten. Exacerbating today's tumble was the CDC's warning to prepare for the outbreak to hit the U.S., it's just a matter of time. The drop in longer dated Treasury yields to fresh record lows added to the angst in equities. Disappointing February data on consumer confidence and the Richmond Fed index piled on, while in the background, Bernie Sanders' socialist agenda was a worry after his big win in Nevada. The 2-year auction was poorly received as the richest yield in over 4 years left potential buyers sidelined. View the summary.

Upgrade
Arkema upgraded to Overweight from Neutral at JPMorgan » 21:30
02/25/20
02/25
21:30
02/25/20
21:30
ARKAY

Arkema

$0.00 /

+ (+0.00%)

JPMorgan analyst Chetan…

JPMorgan analyst Chetan Udeshi upgraded Arkema to Overweight from Neutral with a EUR 110 price target. The analyst believes the presence of an activist serves as a potential catalyst to unlock shareholder value.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Iovance Biotherapeutics price target raised to $40 from $30 at Piper Sandler » 21:02
02/25/20
02/25
21:02
02/25/20
21:02
IOVA

Iovance Biotherapeutics

$31.61 /

+6.92 (+28.03%)

Piper Sandler analyst…

Piper Sandler analyst Joseph Catanzaro raised his price target on Iovance Biotherapeutics to $40 and kept his Outperform rating after its Q4 earnings beat and with the company announcing that its timelines for melanoma and cervical registrational cohort filings remaining unchanged by year-end FY20. The analyst also maintains his view of Iovance as the leader in solid tumor targeting cell therapy and contends that some of its rumored potential acquirers do as well.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Infinera price target raised to $8.50 from $5.50 at Piper Sandler » 20:56
02/25/20
02/25
20:56
02/25/20
20:56
INFN

Infinera

$7.90 /

-0.2 (-2.47%)

Piper Sandler analyst…

Piper Sandler analyst Troy Jensen raised his price target on Infinera to $8.50 after its Q4 earnings beat and with bookings in the quarter exceeding revenues. The analyst further notes that the company has achieved its promise to reach profitability, but also maintains his Neutral rating given the stock's recent outperformance and amid the supply chain concerns.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Northview REIT downgraded to Market Perform from Outperform at BMO Capital » 20:49
02/25/20
02/25
20:49
02/25/20
20:49
NPRUF

Northview REIT

$0.00 /

+ (+0.00%)

BMO Capital analyst Troy…

BMO Capital analyst Troy MacLean downgraded Northview REIT to Market Perform from Outperform with a price target of C$36.25, up from C$30.75. The downgrade follows last week's announced acquisition of the REIT by the Starlight Group with the target price matching the offer price.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Ecopetrol reports Q4 net profit up 51.5% at COP4.01T » 20:36
02/25/20
02/25
20:36
02/25/20
20:36
EC

Ecopetrol

$19.14 /

-0.265 (-1.37%)

Reports Q4 revenue up…

Reports Q4 revenue up 1.5% at COP18.6T. CEO Felip Pardon says: "2019 was an outstanding year for the Ecopetrol group, both operationally and financially, reaching the targets we set in the 2019-2021 Plan update. Our financial results were the highest of the past six years, with a net profit of COP 13.3 trillion, an EBITDA of COP 31.1 trillion and an EBITDA margin of 44%. This performance allowed for the highest dividend payment in the company's history, as well as investments focused on profitable organic and inorganic growth totalling $4.4 billion, maintaining our credit rating. The Gross Debt-to-EBITDA ratio was 1.2 times in 2019."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Rayonier Advanced Materials sees FY20 capex down by $10M-$15M » 20:33
02/25/20
02/25
20:33
02/25/20
20:33
RYAM

Rayonier Advanced Materials

$2.40 /

-0.325 (-11.95%)

Rayonier Advanced…

Rayonier Advanced Materials states: "The company expects to improve costs from operations by $15M primarily through efficiencies in supply chain and execution on continuous improvement projects in its facilities. 2020 working capital will be reduced by an estimated $25M from 2019 levels with a focus on reducing inventory levels and improving payment terms."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Rayonier Advanced Materials reports Q4 EPS (78c), consensus (29c) » 20:32
02/25/20
02/25
20:32
02/25/20
20:32
RYAM

Rayonier Advanced Materials

$2.40 /

-0.325 (-11.95%)

Reports Q4 revenue $468M,…

Reports Q4 revenue $468M, consensus $431.22M. "2019 was a difficult year, negatively impacted by global trade disputes and sales price declines across our commodity businesses. We took decisive action to combat the pressure including implementing a strategy to increase margins in Cellulose Specialties, reduce capital expenditures, sell the Matane asset and reduce debt," said Paul Boynton, CEO. "Today, we are announcing additional cost and cash actions that will position the Company to navigate historically weak commodity markets, ensure debt covenant compliance and ultimately drive long-term success."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Extra Space Storage chairman sells 200K shares of common stock » 20:27
02/25/20
02/25
20:27
02/25/20
20:27
EXR

Extra Space Storage

$106.95 /

-1.86 (-1.71%)

In a regulatory filing,…

In a regulatory filing, Extra Space Storage disclosed that its chairman Kenneth Woolley sold 200K shares of common stock on February 24th-25th. The total transaction size was $21.5M.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Notable companies reporting before tomorrow's open » 20:25
02/25/20
02/25
20:25
02/25/20
20:25
LOW

Lowe's

$118.69 /

-4.215 (-3.43%)

, TJX

TJX

$59.77 /

-1.97 (-3.19%)

, WEN

Wendy's

$22.98 /

-0.425 (-1.82%)

, SEAS

SeaWorld

$29.75 /

-2.9 (-8.88%)

, PZZA

Papa John's

$67.51 /

-0.99 (-1.45%)

, AMCX

AMC Networks

$33.01 /

-1.26 (-3.68%)

, CARS

Cars.com

$10.57 /

-1.48 (-12.28%)

Notable companies…

Notable companies reporting before tomorrow's open, with earnings consensus, include Lowe's (LOW), consensus 91c... TJX Companies (TJX), consensus 77c... Wendy's (WEN), consensus 8c... SeaWorld (SEAS), consensus 2c... Papa John's (PZZA), consensus 32c... AMC Networks (AMCX), consensus $1.78... Cars.com (CARS), consensus 37c.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Morgan Stanley auto analysts to hold an analyst/industry conference call » 20:25
02/25/20
02/25
20:25
02/25/20
20:25
TM

Toyota

$134.02 /

-0.475 (-0.35%)

Auto Analysts discuss…

Auto Analysts discuss Toyota's China strategy and pathway to electrification on an Analyst/Industry conference call to be held on February 25 at 9 pm.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
SPDR Gold Shares holdings rise to 940.09MT from 933.94MT » 20:17
02/25/20
02/25
20:17
02/25/20
20:17
GLD

SPDR Gold Shares

$153.34 /

-2.82 (-1.81%)

This is the largest level…

This is the largest level of holdings since November of 2016.

Initiation
Remy Cointreau initiated with a Buy at Goldman Sachs » 20:14
02/25/20
02/25
20:14
02/25/20
20:14
REMYY

Remy Cointreau

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Olivier Nicolai initiated coverage of Remy Cointreau with a Buy rating and EUR 125 price target. The analyst notes that after a 30% decline in the stock price from the September peak due to coronavirus fears in Hong Kong, the weakness offers an attractive opportunity. Nicolai adds that Remy is heading for a 24% organic sales growth decline in Q4, but the company will benefit from the "premiumisation" trend given its strong positioning in the super premium segment.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Fevertree Drinks initiated with a Sell at Goldman Sachs » 20:07
02/25/20
02/25
20:07
02/25/20
20:07
FQVTF

Fevertree Drinks

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Olivier Nicolai initiated coverage of Fevertree Drinks with a Sell rating and 1350 GBp price target. The analyst warns that the company is headed for another disappointing year in the U.K. markets due to the slowdown in the gin category and with less upside coming from its distribution gains, adding that there are no obvious catalysts for trends to improve in FY20.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Campari initiated with a Neutral at Goldman Sachs » 19:58
02/25/20
02/25
19:58
02/25/20
19:58
DVDCY

Campari

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Olivier Nicolai initiated coverage of Campari with a Neutral rating and EUR 9.0 price target. The analyst notes that the company offers a proven track record of delivering superior organic sales growth combined with value creation from M&A, but sees its operating leverage as limited until FY21 due to agave price inflation and the impact of U.S. tariffs on certain imports.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Coca-Cola HBC initiated with a Neutral at Goldman Sachs » 19:55
02/25/20
02/25
19:55
02/25/20
19:55
CCHGY

Coca-Cola HBC

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Olivier Nicolai initiated coverage of Coca-Cola HBC with a Neutral rating and 2940 GBp price target. The analyst notes that the company's current valuation multiple of 21-times expected forward earnings captures the growth potential of its expected 5% organic revenue growth, even though he sees potential opportunities related to its conservative balance sheet and the roll-out of the Costa brand beginning this year.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Heineken initiated with a Neutral at Goldman Sachs » 19:51
02/25/20
02/25
19:51
02/25/20
19:51
HEINY

Heineken

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Olivier Nicolai initiated coverage of Heineken with a Neutral rating. The analyst sees the company driving organic revenue growth of about 5% over the medium term given its diversified geographic footprint with exposure to a growing profit pool in Africa, Latin America, and Asia Pacific. Nicolai adds however that questions around the other key markets are preventing him from having a more positive stance.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Carlsberg initiated with a Sell at Goldman Sachs » 19:49
02/25/20
02/25
19:49
02/25/20
19:49
CABGY

Carlsberg

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Olivier Nicolai initiated coverage of Carlsberg with a Sell rating and DKK 930 price target. The analyst notes that the company has had a good track record of higher margins, returns, and growth in recent years, but with the stock trading near an all-time high relative multiples, he sees some scope for downgrades.. Nicolai adds that Carlsberg's further margin pressure in Russia has not been fully captured by consensus.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Diageo initiated with a Buy at Goldman Sachs » 19:45
02/25/20
02/25
19:45
02/25/20
19:45
DGEAF

Diageo

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Olivier Nicolai initiated coverage of Diageo with a Buy rating and 3600 GBp price target. The analyst is positive on the company's reliable sales growth, superior returns, and balance sheet optionality with a track record of being a high-quality compounder. Nicolai adds that even given the coronavirus impact, his earnings target for FY21/22 is 2% ahead of consensus.

Initiation
AB InBev initiated with a Neutral at Goldman Sachs » 19:40
02/25/20
02/25
19:40
02/25/20
19:40
BUD

AB InBev

$66.85 /

-2.51 (-3.62%)

Goldman Sachs analyst…

Goldman Sachs analyst Olivier Nicolai initiated coverage of AB InBev with a Neutral rating and $77 price target. The analyst believes that the company is able to regain its best-in-class status in the fast-moving consumer goods category given its global footprint, premium brand portfolio, and superior cash generation. However, Nicolai is also concerned with InBev's current macro headwinds, strong USD, and high leverage.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Britvic initiated with a Buy at Goldman Sachs » 19:33
02/25/20
02/25
19:33
02/25/20
19:33
BTVCF

Britvic

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Richard Felton initiated coverage of Britvic with a Buy rating and 1,120 GBp price target. The analyst contends that the company is among the cheapest stocks in European consumer staples and is positive on its recent transformational capex program which has "materially upgraded its supply chain". Felton contends that the efforts should unlock new growth opportunities for the company.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Pernod Ricard initiated with a Buy at Goldman Sachs » 19:30
02/25/20
02/25
19:30
02/25/20
19:30
PDRDY

Pernod Ricard

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Olivier Nicolai initiated coverage of Pernod Ricard with a Buy rating and EUR 195 price target. The analyst cites the company's attractive "growth algorithm" in European consumer staples, organic revenue growth of 6%-7%, and upside from lower tax and finance costs that he contends are not reflected in consensus, anticipating 13% earnings growth through FY24.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Fly Intel: After Hours Movers » 19:05
02/25/20
02/25
19:05
02/25/20
19:05
ACRS

Aclaris Therapeutics

$1.38 /

-0.04 (-2.82%)

, WW

WW

$34.84 /

-2.05 (-5.56%)

, MTDR

Matador

$10.88 /

-1.32 (-10.82%)

, BGS

B&G Foods

$12.78 /

-0.33 (-2.52%)

, ALRM

Alarm.com

$44.82 /

-1.46 (-3.15%)

, NVRO

Nevro

$132.50 /

-3.01 (-2.22%)

, INFN

Infinera

$7.90 /

-0.2 (-2.47%)

, EVH

Evolent Health

$10.18 /

-1.13 (-9.99%)

, PRTK

Paratek Pharmaceuticals

$3.58 /

+0.04 (+1.13%)

, ADMS

Adamas Pharmaceuticals

$4.77 /

-0.47 (-8.97%)

, AKCA

Akcea Therapeutics

$17.09 /

+0.29 (+1.73%)

, SDC

SmileDirectClub

$11.33 /

-0.51 (-4.31%)

, RVLV

Revolve Group

$19.93 /

+1 (+5.28%)

, SUPN

Supernus

$22.93 /

-1.04 (-4.34%)

, PODD

Insulet

$197.03 /

-10.46 (-5.04%)

, SCCO

Southern Copper

$35.05 /

-1.09 (-3.02%)

, TOL

Toll Brothers

$44.28 /

-2.765 (-5.88%)

, VICR

Vicor Corporation

$47.89 /

-0.14 (-0.29%)

, PEN

Penumbra

$176.15 /

-8.13 (-4.41%)

, UIS

Unisys

$15.88 /

-0.405 (-2.49%)

, PLNT

Planet Fitness

$81.51 /

-2.87 (-3.40%)

, SPCE

Virgin Galactic

$33.65 /

-0.51 (-1.49%)

, REAL

RealReal

$14.99 /

+0.03 (+0.20%)

, ORA

Ormat Technologies

$79.94 /

-3.12 (-3.76%)

, IOVA

Iovance Biotherapeutics

$31.61 /

+6.92 (+28.03%)

, EXEL

Exelixis

$19.42 /

-0.76 (-3.77%)

, EVTC

Evertec

$31.36 /

-0.65 (-2.03%)

, CRM

Salesforce

$181.65 /

-4.26 (-2.29%)

, JAZZ

Jazz Pharmaceuticals

$127.50 /

-3.31 (-2.53%)

, CZR

Caesars

$13.33 /

-0.69 (-4.92%)

, AMRN

Amarin

$17.54 /

-0.05 (-0.28%)

, RRGB

Red Robin

$31.32 /

-3.84 (-10.92%)

, VNDA

Vanda Pharmaceuticals

$11.51 /

-0.28 (-2.37%)

, DIS

Disney

$128.24 /

-4.79 (-3.60%)

UP AFTER EARNINGS:…

UP AFTER EARNINGS: Aclaris (ACRS) up 8.0%... WW International (WW) up 6.8%... Matador Resources (MTDR) up 6.0%... B&G Foods (BGS) up 5.7%... Alarm.com (ALRM) up 5.3%... Nevro (NVRO) up 3.4%... Infinera (INFN) up 3.4%... Evolent Health (EVH) up 3.1%... Paratek Pharma (PRTK) up 2.8%... Adamas Pharma (ADMS) up 1.9%... Akcea Therapeutics (AKCA) up 1.9%. DOWN AFTER EARNINGS: SmileDirectClub (SDC) down 20.5%... Revolve Group (RVLV) down 18.1%... Supernus Pharma (SUPN) down 15.0%... Insulet (PODD) down 12.1%... Southern Copper (SCCO) down 9.3%... Toll Brothers (TOL) down 9.0%... Vicor Corp (VICR) down 8.7%... Penumbra (PEN) down 6.9%... Unisys (UIS) down 6.1%... Planet Fitness (PLNT) down 5.9%... Virgin Galactic (SPCE) down 5.7%... RealReal (REAL) down 5.1%... Ormat Technologies (ORA) down 3.8%... Iovance Biotherapeutics (IOVA) down 3.1%... Exelixis (EXEL) down 3.1%... Evertec (EVTC) down 3.0%... Salesforce (CRM) down 2.1%... Jazz Pharma (JAZZ) down 1.8%... Caesars (CZR) down 1.6%... Amarin Corp (AMRN) down 1.4%... Red Robin (RRGB) down 1.3%. ALSO LOWER: Vanda Pharma (VNDA) down 7.6% after Phase 3 study of tradipitant did not meet primary endpoint... Disney (DIS) down 1.7% after naming new CEO. Movers as of 18:30ET.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.